Skip to main content
Infection and Immunity logoLink to Infection and Immunity
. 1982 Nov;38(2):558–562. doi: 10.1128/iai.38.2.558-562.1982

Increased severity of urinary tract infection and bacteremia in mice with urinary bladder injury induced by cyclophosphamide.

D Lyon, E B Howard, J Z Montgomerie
PMCID: PMC347775  PMID: 7141706

Abstract

The effect of cyclophosphamide on urinary tract infection was studied, using Pseudomonas aeruginosa in a murine model. Urinary tract infections were produced by injecting P. aeruginosa through a urethral catheter into the bladders of mice. The number of P. aeruginosa organisms in the bladder tissue and kidneys, histopathology, peripheral leukocyte count, and antibody response to P. aeruginosa was measured. The local effect of cyclophosphamide on the bladder was determined by measuring the bladder tissue water and examining the histopathology. Cyclophosphamide increased the susceptibility of mice to P. aeruginosa urinary tract infection, resulting in marked cystitis and an increase in renal infection, bacteremia, and mortality. These changes correlated with the toxic effect of cyclophosphamide on the wall of the bladder rather than with peripheral leukopenia or failure of antibody response.

Full text

PDF
558

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cox P. J. Cyclophosphamide cystitis--identification of acrolein as the causative agent. Biochem Pharmacol. 1979 Jul 1;28(13):2045–2049. doi: 10.1016/0006-2952(79)90222-3. [DOI] [PubMed] [Google Scholar]
  2. Goldman R. L., Warner N. E. Hemorrhagic cystitis and cytomegalic inclusions in the bladder associated with cyclophosphamide therapy. Cancer. 1970 Jan;25(1):7–11. [PubMed] [Google Scholar]
  3. Holmgren J., Svennerholm A. M. Enzyme-linked immunosorbent assays for cholera serology. Infect Immun. 1973 May;7(5):759–763. doi: 10.1128/iai.7.5.759-763.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Johnson W. W., Meadows D. C. Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy. N Engl J Med. 1971 Feb 11;284(6):290–294. doi: 10.1056/NEJM197102112840602. [DOI] [PubMed] [Google Scholar]
  5. Levine A. S., Schimpff S. C., Graw R. G., Jr, Young R. C. Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol. 1974 Apr;11(2):141–202. [PubMed] [Google Scholar]
  6. Levy L., Harris R. Effect of N-acetylcysteine on some aspects of cyclophosphamide-induced toxicity and immunosuppression. Biochem Pharmacol. 1977 Jun 1;26(11):1015–1020. doi: 10.1016/0006-2952(77)90237-4. [DOI] [PubMed] [Google Scholar]
  7. Montgomerie J. Z., Tuddenham W. J., Howard E. B., Morrow J. W. Pseudomonas urinary tract infection in mice. Infect Immun. 1980 Jul;29(1):267–270. doi: 10.1128/iai.29.1.267-270.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. PHILIPS F. S., STERNBERG S. S., CRONIN A. P., VIDAL P. M. Cyclophosphamide and urinary bladder toxicity. Cancer Res. 1961 Dec;21:1577–1589. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES